T lymphocytes and B lymphocytes make up the adaptive immune system. When CLL treatment destroys them both, patients become highly susceptible to life-threatening infections.
“A drug that kills malignant B lymphocytes and spares T lymphocytes could dramatically improve outcomes for CLL patients,” says study leader Dr. John C. Byrd, director, division of hematology and professor of medicine, of medicinal chemistry and of veterinary biosciences at the OSUCCC – James.
“Our collective results indicate that PCI-32765 is an outstanding candidate for further development as a therapeutic for CLL,” says study co-director Dr. Amy J. Johnson, assistant professor of hematology and medicinal chemistry, and a CLL researcher with the OSUCCC-James.
The research by Byrd, Johnson and a group of colleagues used CLL cells from ten patients. It had several key findings related to PCI-32765:
- The agent specifically targets an important signaling molecule called Bruton’s tyrosine kinase, which is overexpressed in CLL cells and absent in T cells.
- The agent inhibits the proliferation of CLL cells in laboratory culture and promotes their death by self-destruction (apoptosis).
- It blocks survival signals from cells in the surrounding microenvironment, including soluble factors such as IL-6, IL-4, and TNF-a, and stromal-cell contact.
Byrd is the D. Warren Brown Chair of Leukemia Research.
Funding from The Leukemia and Lymphoma Society, the National Cancer Institute and The D. Warren Brown Foundation supported this work.
Other researchers involved in this study were Sarah E. M. Herman, Amber L. Gordon, Erin Hertlein, Asha Ramanunni, Xiaoli Zhang, Samantha Jaglowski, Joseph Flynn, Jeffrey Jones and Kristie A. Blum of The Ohio State University; and Joseph J. Buggy and Ahmed Hamdy of Pharmacyclics, Inc.
Financial disclosure: Joseph J. Buggy and Ahmed Hamdy are employees of Pharmacyclics, Inc. and both have financial interests in PCI-32765 development.
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (http://cancer.osu.edu) is one of only 40 Comprehensive Cancer Centers in the United States designated by the National Cancer Institute. Ranked by U.S. News & World Report among the top cancer hospitals in the nation, The James is the 205-bed adult patient-care component of the cancer program at The Ohio State University. The OSUCCC-James is one of only seven programs in the country funded by the NCI to conduct both Phase I and Phase II clinical trials.
- A high quality JPEG of John C. Byrd, MD, is available here.
- A high quality JPEG of Amy J. Johnson, PhD, is available here.
Darrell E. Ward
Medical Center Communications